Impact of Genetic Targets on Cancer Therapy

1. Front Matter

   Pages i-viii

   PDF

2. Novel Antineoplastics Targeting Genetic Changes in Colorectal Cancer

   • Jamal Joudeh, Joshua E. Allen, Avisnata Das, Varun Prabhu, Michael Farbaniec, Jeffrey Adler et al.

   Pages 1-34

3. Update on Clinical Trials: Genetic Targets in Breast Cancer

   • Bora Lim, Leah V. Cream, Harold A. Harvey

   Pages 35-54

4. Impact of Genetic Targets on Cancer Therapy in Esophagogastric Cancer

   • Yixing Jiang

   Pages 55-65

5. Impact of Genetic Targets on Cancer Therapy: Hepatocellular Cancer

   • Osama Hamed, Eric T. Kimchi, Mandeep Sehmbey, Niraj J. Gusani, Jussuf T. Kaifi, Kevin Staveley-O’Carroll

   Pages 67-90

6. Toward the Goal of Personalized Therapy in Pancreatic Cancer by Targeting the Molecular Phenotype

   • Nelson S. Yee

   Pages 91-143

7. Impact of Genetic Markers on Treatment of Non-small Cell Lung Cancer

   • Nicholas Lamparella, Amit Barochia, Salah Almokadem

   Pages 145-164

8. Impact of Genetic Targets on Therapy in Head and Neck Squamous Cell Carcinoma

   • Irina Chaikhoutdinov, David Goldenberg

   Pages 165-177

9. Tyrosine Kinase Targeted Treatment of Chronic Myelogenous Leukemia and Other Myeloproliferative Neoplasms

   • Ajit Bisen, David F. Claxton

   Pages 179-196

10. Targeted Therapy of Multiple Myeloma

    • Nathan G. Dolloff, Giampaolo Talamo

    Pages 197-221

11. Current and Future Trials of Targeted Therapies in Cutaneous Melanoma

    • Matthew S. Evans, SubbaRao V. Madhunapantula, Gavin P. Robertson, Joseph J. Drabick

    Pages 223-255

12. Current Approaches to Epigenetic Therapy for the Treatment of Mantle Cell Lymphoma

    • Vikas Ghai, Kamal Sharma, Kamal K. S. Abbi, Sara Shimko, Elliot M. Epner

    Pages 257-266

13. Impact of Genetic Targets on Primary Brain Tumor Therapy: What’s Ready for Prime Time?

    • O. Zalatimo, C. M. Zoccoli, A. Patel, C. L. Weston, M. Glantz

    Pages 267-289

14. Rational Therapy for Renal Cell Carcinoma Based on its Genetic Targets

    • Jamie Messer, Joseph Drabick, Matthew Kaag

    Pages 291-308

15. Molecular and Genetic Markers of Follicular-Cell Thyroid Cancer: Etiology and Diagnostic and Therapeutic Opportunities

    • Neerav Goyal, Dhave Setabutr, Junaid Abdulghani, David Goldenberg

    Pages 309-326

16. Genetic Targets in Pediatric Acute Lymphoblastic Leukemia

    • Chandrika Gowda, Sinisa Dovat

    Pages 327-340

17. Emerging Molecular Therapies for the Treatment of Acute Lymphoblastic Leukemia

    • Monali Vasekar, Joshua E. Allen, Jamal Joudeh, David Claxton

    Pages 341-358

18. Impact of Genetic Targets on Prostate Cancer Therapy

    • Hassan Sheikh, Junaid Abdulghani, Suhail Ali, Raghu Sinha, Alan Lipton

    Pages 359-383

19. Small-Cell Lung Cancer: An Update on Targeted Therapies

    • Monika Joshi, Ayodele Ayoola, Chandra P. Belani

    Pages 385-404

20. Impact of Genetic Targets on Cancer Therapy in Acute Myelogenous Leukemia

    • Mithun Vinod Shah, Amit Barochia, Thomas P. Loughran Jr.

    Pages 405-437

​​​The volume provides a forum for original peer-reviewed short communications, full-length research and review articles on new research findings and developments on the topic of genetic targets on cancer therapies. As the field is highly important it requires co-operation between research communities from all over the world to share their knowledge and experience in order to move the field forward. Each chapter includes a discussion of the impact of the tumor microenvironment and cancer stem cells and cover current knowledge in this area as it pertains to the disease, including emerging therapy targeting the microenvironment and/or cancer stem cells.

• antineoplastics
• epigenetics
• genetic markers
• genetic targets
• molecular phenotype

• Hershey, USA

  Wafik S El-Deiry

Wafik S. El-Deiry, M.D., Ph.D, is Professor of Medicine, Chief, Hematology/Oncology, Rose Dunlap Division Chair in Hematology/Oncology, and Associate Director for Translational Researchat Penn State Hershey Cancer Institute. Dr. El-Deiry is a well-respected and notable figure among cancer researchers, scientists, and clinicians. He has published almost 300 papers in his career and has over 29,000 totol citations, with an excellent h-index of 70.

Policies and ethics